Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD

BACKGROUND: Recent evidence suggests the systemic accumulation of by-products of gut microbes contributes to cardiovascular morbidity in patients with CKD. Limiting the generation of toxic bacterial by-products by manipulating the intestinal microbiota may be a novel strategy for reducing cardiovasc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Kidney360
Hlavní autoři: Kimber, Cassandra, Zhang, Shiqin, Johnson, Cassandra, West, Raymond E., Prokopienko, Alexander J., Mahnken, Jonathan D., Yu, Alan S., Hoofnagle, Andrew N., Ir, Diana, Robertson, Charles E., Miyazaki, Makoto, Chonchol, Michel, Jovanovich, Anna, Kestenbaum, Bryan, Frank, Daniel N., Nolin, Thomas D., Stubbs, Jason R.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Nephrology 2020
Témata:
Original Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8315698/
https://ncbi.nlm.nih.gov/pubmed/34322673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.34067/KID.0003942020
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky